Gene · 10057
Papers1,907
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,907
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Integrated network toxicology, machine learning, and multi-omics characterization of 2,4-DTBP neurotoxicity. | Chem Biol Interact | 2026 | 42822756 | PubTator, text mining | PubMed |
| Disrupting KRAS-AGO2 interaction: a dual-pronged strategy to sensitize chemo-immunotherapy in KRAS-mutated colorectal cancer. | Apoptosis | 2026 | 42622908 | PubTator, text mining | PubMed |
| A conserved vesicular circuit enables metabolic adaptation and maintains systemic heme homeostasis. | bioRxiv | 2026 | 42620181 | PubTator, text mining | PubMed |
| Interleukin-1β and Interleukin-6 Signaling Differentially Regulate ABC Transporter Activity and Amyloid-β Handling in Primary Porcine Brain Endothelial Cells. | Cells | 2026 | 42505383 | PubTator, text mining | PubMed |
| Pharmacogenetic mechanism of cilostazol-induced headaches: Splicing-mediated loss of ABCC5 gene function. | Br J Pharmacol | 2026 | 42485569 | PubTator, text mining | PubMed |
| Bis-(di-4-phenyl-benzylaminethiocarbonyl)disulfide sensitizes ABCC2/ALDH3A1 overexpressing NSCLC cells to cisplatin. | Cancer Biol Ther | 2026 | 42474358 | PubTator, text mining | PubMed |
| Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study. | Br J Clin Pharmacol | 2026 | 42220058 | PubTator, text mining | PubMed |
| Development of liposomal pemetrexed for enhanced therapy against multidrug resistance mediated by ABCC5 in breast cancer [Retraction]. | Int J Nanomedicine | 2026 | 42205871 | PubTator, text mining | PubMed |
| Influence of inflammation on drug transporter expression in human airway epithelia: Implications for inhaled drug pharmacokinetics. | Drug Metab Dispos | 2026 | 42066732 | PubTator, text mining | PubMed |
| Stigmasterol reverses rituximab resistance in diffuse large B-cell lymphoma via the MAPK1 signaling pathway. | Transl Cancer Res | 2026 | 41969461 | PubTator, text mining | PubMed |
| Comparative effectiveness of 7 major human let-7-5p isoforms to modulate target gene expression in liver cells. | Drug Metab Dispos | 2026 | 41905330 | PubTator, text mining | PubMed |
| Pharmacological evaluation of an ex vivo cervicovaginal HIV prevention model. | J Antimicrob Chemother | 2026 | 41873439 | PubTator, text mining | PubMed |
| Globo H ceramide confers chemoresistance and poor prognosis to advanced gallbladder cancer via A2AR/cAMP/PKA pathway. | Theranostics | 2026 | 41799195 | PubTator, text mining | PubMed |
| Deciphering sorafenib resistance in hepatocellular carcinoma via ferroptotic mechanisms. | Biochim Biophys Acta Rev Cancer | 2026 | 41763496 | PubTator, text mining | PubMed |
| Region-Specific NRF2 Signaling in HIV-Associated Neurocognitive Disorders: A Transcriptomic and Computational Histology Study. | Genes (Basel) | 2026 | 41751579 | PubTator, text mining | PubMed |
4-(5-Chloro-3-(3,4,5-trimethoxybenzoyl)-1H-indol-1-yl)benzenesulfonamide: A Novel Polypharmacology Agent to Target Carbonic Anhydrase IX and XII With Improved Selectivity, Wnt/β-Catenin Signaling Pathway, and P-Glycoprotein. | ChemMedChem | 2026 | 41739665 | PubTator, text mining | PubMed |
| Consequences of irradiation on blood-brain tumor barrier model of Diffuse Midline Glioma: characterization of physical and metabolic properties. | Fluids Barriers CNS | 2026 | 41736134 | PubTator, text mining | PubMed |
| An integrative genomic framework to identify remote ischemic preconditioning-responsive genes associated with stroke risk. | Exp Neurol | 2026 | 41690496 | PubTator, text mining | PubMed |
| Optimization of potential targets for antidepressant Chinese medicines: AI and multi-omics methods. | Chin Med | 2026 | 41668206 | PubTator, text mining | PubMed |
| Expression of drug transporters in human allogenic transplanted kidneys in acute rejection. | Toxicol Appl Pharmacol | 2026 | 41581572 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10057/papers